New drug for postpartum depression – a response to the New York Times
On 25th March 2019 the New York Times published this article about a new drug treatment for postpartum depression: “Can a Drug Stop Postpartum Depression?,”
Below is our clinical team’s response to this article:
As mental health professionals with expertise in perinatal mental health, we appreciate many of the thoughts expressed here, including the description of Zulresso, a new and potentially powerful medication to treat significant and serious postpartum depression. While we do have concerns that this medication might have very limited availability because of the significant cost and that it’s only administered in an inpatient setting, we are glad to see advances in the care of women experiencing severe depression in the postpartum time. We also appreciate that the significant lack of postpartum care and support in the United States was addressed.
But reference to the lack of support, which indeed and can contribute to anxiety and depression among new mothers, in the context of an article about a ‘heavyweight’ drug like Zulresso tends to conflate severe depressive states in the postpartum time with entirely normal perinatal adjustment issues, including emotional instability and distress.
Let’s be clear, the women who need this drug are likely to need hospitalization. They are experiencing severe postpartum depression that is actually a psychiatric crisis. These reactions to new motherhood are not normal. This is not routine baby blues.
Conflating normal adjustment and emotional distress with a serious psychiatric disorder will frighten postpartum women and, ironically, stigmatize mental health issues. Furthermore, this conflation runs a serious risk of missing a psychiatric crisis through mistakenly thinking “this emotional distress is normal.” On the other hand, an erroneous diagnosis of serious depression in the case of normal perinatal emotional distress is equally poor clinical care and potentially stigmatizing, too.
In recent years, there have been great advances in our understanding of emotional distress in the peripartum time and we are developing new tools for clinical care, which includes the knowledge that helps us distinguish normal emotional distress from a psychiatric emergency.
Sarah Mallin, director of operations with Boram Postnatal Retreat, was a NICU nurse when she was pregnant. She shares her story of how she was able to overcome overwhelming anxiety both during and after pregnancy and offers hope and inspiration for others in this Seleni Spotlight story.
Seleni’s executive director, Seema Bajaj, candidly breaks down the misconception surrounding stress and infertility and provides practical guidance on how we can better support our loved ones going through the emotional rollercoaster of infertility treatment.
Dr. Marissa Long, instructor of the Black Perinatal Mental Health training, and Dr. Tamika Simpson reflect on this year’s Black Maternal Health Week.
Distinguishing normal emotional distress from a psychiatric emergency.
Perinatal anxiety is starting to get the scientific attention it deserves
Both medical and mental health practices are seeing an uptick in patient concern
Why we need better efforts to reach women at higher risk
What increases a woman's risk, programs that are working, and what we still need